Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2000

View Archived Issues

Creative BioMolecules' OP-1 Implant enters regulatory review process during Q3 1999

Cell Genesys receives payment from Japan Tobacco

Phase II study of Fabry's disease treatment successfully completed

Medarex and IDM establish broad collaborative agreement

Interneuron signs major partnerships and focuses resources during 1999

Company Profile: Onyvax

Levotech completes phase IIb study of seven-day contraceptive patch

Cell Based Delivery receives NIST grant for cardiovascular program

Immunomedics/IBC develop new fusion protein for use in cancer therapy

Incara completes sale of antibacterial division

Nonpeptide endothelin antagonists from Warner-Lambert selective for ETA receptors

Abbott investigates new compounds for angiogenesis-related disorders

Preparation and use of MMP inhibitors described by Bayer

Merck describes thrombin-specific anticoagulants

Centaur's new NRTs and their use for treating, preventing IBD

Phenylalanine derivatives selective for alpha4 integrins discovered by Celltech

Specific VLA-4 inhibitor designed at Biogen for cell adhesion-mediated pathologies

Metabotropic glutamate receptor agonist tested in anxiety and addiction models

SmithKline Beecham patents novel ERK/MAP kinase inhibitors

NDA filed for intranasal scopolamine during fourth quarter

Antiangiogenic activity of troponin I may involve direct inhibition of bFGF and VEGF receptors

CFC-free flunisolide to be developed by 3M/Forest partnership

ViroPharma licenses Battelle's drug delivery technology for its anti-RSV products

Preclinical pharmacokinetics of SB-240563 support clinical development for asthma

Potent new nonpeptide bradykinin B2 receptor antagonist selected by Fournier for further development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...